Composition comprising antisense oligonucleotide and use thereof for treatment of duchenne muscular dystrophy

A pharmaceutical composition for treating a human patient with Duchenne muscular dystrophy (DMD) comprising an antisense oligomer, a pharmaceutically acceptable salt thereof, or a hydrate thereof in a concentration of between 2.5 mg/ml inclusive and 500 mg/ml inclusive,

• wherein the antisense oligomer consists of a base sequence complementary to a sequence consisting of nucleotides at positions 36 to 56 from the 5′-terminus of exon 53 of a human dystrophin gene.